Stat5, a cellular signaling protein activated in almost all recurrent prostate cancers resistant to hormone therapy, may be used as a target to develop drugs for the disease, researchers concluded. The study established a link between Stat5 and the hormone androgen, and plans to test the interaction to see whether it produces androgen-independent prostate tumor growth.

Related Summaries